Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

920
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
920
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

869
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
869
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

801
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

721
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
721
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

805
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
805
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

472
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
472

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variant Site-Specific Natural History of Titin-Induced Cardiomyopathy: An International Multicenter Registry.

Circulation. Genomic and precision medicine·2026
Same author

Natural History of Asymptomatic Phenotypically Mild HCM: Insights From the SHaRe Registry.

Journal of the American College of Cardiology·2026
Same author

Metabolic crisis and TRPM4 activation cause QT prolongation in TANGO2 deficiency disorder.

Cardiovascular research·2026
Same author

Thick filament molecular interfaces play a critical role in the pathogenesis of hypertrophic cardiomyopathy.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Different actions of RyR2 open and closed channel block explained by a multiscale Ca<sup>2+</sup> release model.

Biophysical journal·2026
Same author

Prioritizing Discovery and Advancements in Arrhythmia Therapies: NIH/NHLBI Workshop.

JACC. Clinical electrophysiology·2026

Related Experiment Video

Updated: Apr 18, 2026

Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.
08:37

Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.

Published on: March 3, 2021

5.0K

Research priorities in sarcomeric cardiomyopathies.

Jolanda van der Velden1, Carolyn Y Ho2, Jil C Tardiff3

  • 1Department of Physiology, Institute for Cardiovascular Research (ICaR-VU), VU University Medical Center, van der Boechorststraat 7, 1081BT Amsterdam, The Netherlands ICIN-Netherlands Heart Institute, Utrecht, The Netherlands j.vandervelden@vumc.nl l.carrier@uke.de.

Cardiovascular Research
|January 30, 2015
PubMed
Summary

Sarcomeric cardiomyopathies show striking clinical variability. Understanding mutation-specific mechanisms is crucial for developing personalized therapies, moving beyond a one-size-fits-all approach.

Keywords:
CardiomyopathyMutationSarcomere

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K
In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes
08:19

In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes

Published on: June 22, 2020

7.3K

Related Experiment Videos

Last Updated: Apr 18, 2026

Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.
08:37

Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.

Published on: March 3, 2021

5.0K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K
In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes
08:19

In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes

Published on: June 22, 2020

7.3K

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Molecular Biology

Background:

  • Sarcomeric cardiomyopathies exhibit significant clinical variability, with identical mutations causing disease in some individuals and being benign in others.
  • Phenotypic presentation ranges widely, from asymmetric hypertrophy to severe cardiac dilatation, complicating treatment strategies.

Purpose of the Study:

  • To investigate the underlying mechanisms driving the diverse clinical phenotypes in sarcomeric cardiomyopathies.
  • To advocate for an integrative physiology approach for developing patient/gene-tailored therapies.

Main Methods:

  • Review of clinical observations and basic science knowledge of sarcomere function.
  • Emphasis on the need for meticulous clinical and basic studies to unravel mutation-induced changes.
  • Call for integration of longitudinal clinical studies with mechanistic insights from novel cardiac muscle systems and animal models.

Main Results:

  • Evidence suggests a single, universal disease mechanism is unlikely for all sarcomeric cardiomyopathies.
  • Understanding the initial and progressive changes caused by sarcomere mutations is key to explaining opposing phenotypes.

Conclusions:

  • A 'one size fits all' therapy is inadequate for sarcomeric cardiomyopathies.
  • An integrative, multidisciplinary approach combining clinical, molecular, and physiological studies is essential for developing effective, personalized treatments and improving risk stratification.